Securities Code: 002581
Securities Abbreviation: *ST Weiming
Announcement Number: 2026-032
Shandong Weiming Pharmaceutical Co., Ltd.
Announcement on Director Resignation, Election of Independent Directors and Directors of the Sixth Board of Directors, and Adjustment of Members of the Board's Special Committees
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
Shandong Weiming Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the Thirteenth Meeting of the Sixth Board of Directors on June 25, 2026, and reviewed and approved the "Proposal on Electing Directors of the Sixth Board of Directors," the "Proposal on Electing Independent Directors of the Sixth Board of Directors," and the "Proposal on Adjusting Members of the Board's Special Committees." The relevant matters are hereby announced as follows:
I. Explanation of Director Resignation
The Board of Directors recently received a written resignation report from Director Huang Guiyuan. Mr. Huang Guiyuan has applied to resign from his position as a director of the Company due to personal reasons, and concurrently resign from his position as a member of the Audit Committee of the Sixth Board of Directors. After his resignation, Mr. Huang Guiyuan will no longer hold any positions in the Company.
Given that Mr. Huang Guiyuan's resignation will result in the Audit Committee having fewer than three members, in accordance with the "Company Law of the People's Republic of China," "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 1 - Standardized Operation of Main Board Listed Companies," and the "Articles of Association," etc., to ensure the normal operation of the Company's Board of Directors, Mr. Huang Guiyuan's resignation will take effect after the Company convenes a shareholders' meeting to elect new directors and the Board adjusts its special committee members. Before the new directors and Audit Committee members take office, Mr. Huang Guiyuan will continue to perform his duties as a director and his corresponding responsibilities in the Board's Audit Committee in accordance with relevant laws, regulations, and the "Articles of Association."
As of the date of this announcement, Mr. Huang Guiyuan holds 2,842,000 stock options granted but not yet exercised. The Company will cancel these stock options in accordance with relevant regulations. Mr. Huang Guiyuan has no outstanding commitments that should be fulfilled. He will complete the handover in accordance with the Company's "Management System for Resignation of Directors and Senior Management Personnel."
During his tenure as a director and member of the Audit Committee, Mr. Huang Guiyuan has diligently performed his duties and obligations as a director, providing valuable opinions and suggestions for the Company's scientific decision-making and healthy development. The Company and the Board of Directors express their sincere gratitude for Mr. Huang Guiyuan's contributions during his tenure.
II. Election of Independent Directors and Directors
In addition to the resignation of the director mentioned above, Ms. Cai YanHong, an independent director of the Company, applied to resign from her position as an independent director on May 2026 due to personal reasons. For details, please refer to the "Announcement on the Resignation of Independent Directors" disclosed on the Juchao Information Network (www.cninfo.com.cn) on May 14, 2026.
To improve the corporate governance structure and ensure the standardized operation of the Company's